Radiation Without Surgery: How SBRT Is Changing Treatment for Breast Cancer Liver Metastases

Table of Contents

• Key Points
• Understanding the Problem: Breast Cancer Liver Metastases
• The Rise of Local Treatments for Oligometastases
• Surgery: The Traditional First Choice — and Its Limits
• Other Local Treatment Options and Their Drawbacks
• What Exactly Is SBRT?
• Who Can Receive SBRT for Liver Metastases?
• How SBRT Is Delivered: The Treatment Procedure
• Radiation Doses Used in SBRT
• Protecting Healthy Organs: Dose Constraints
• Combining SBRT with Systemic Therapy
• Treatment Results: What Studies Show
• Predictors of Success: Who Benefits Most?
• Side Effects and Toxicity: How Safe Is SBRT?
• Radiation-Induced Liver Disease: A Key Concern
• Conclusions: Where SBRT Stands Today
• Limitations of the Current Evidence
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• SBRT delivers precise, high-dose radiation to breast cancer liver metastases in 1–6 sessions, sparing healthy liver.
• In studies, 1-year local control ranges from 70% to 100%; serious side effects occur in under 5%.
• Breast cancer origin is a favorable prognostic factor for liver SBRT, with excellent control and survival in trials.
• Eligibility typically includes up to 5 metastases each ≤6 cm, Child-Pugh A, and adequate healthy liver volume.
• SBRT complements systemic therapy; no increased side effects have been reported when combining treatments.

Understanding the Problem: Breast Cancer Liver Metastases

The liver is one of the most common sites where solid tumors — including breast cancer — spread. When breast cancer cells travel to the liver, the condition is called breast cancer liver metastasis (BCLM), and it represents a challenging clinical scenario. The numbers are sobering: liver metastases develop in approximately 50% of all patients with metastatic breast cancer, and in 5–12% of patients, the liver is the primary (first) site of breast cancer recurrence.

The prognosis for BCLM has historically been poor. Without any treatment, survival is just 4–8 months. Even with modern systemic therapies such as chemotherapy and hormone therapy, the average survival extends to only 18–24 months. These figures underscore why researchers have been searching for better ways to control disease in the liver and improve long-term outcomes.

The Rise of Local Treatments for Oligometastases

For decades, the standard approach to advanced breast cancer was systemic therapy — hormone therapy and/or chemotherapy given with the goal of palliation (relieving symptoms and extending life) rather than cure. Local treatments like surgery or radiation were used infrequently.

That thinking has changed dramatically. A concept called "oligometastases" — meaning a limited number of metastatic spots (typically five or fewer) — has gained widespread acceptance. The idea is that when cancer has spread to only a few locations, aggressively treating those spots with curative intent could improve disease control and overall survival. This has opened the door for local therapies, including radiation, to play a meaningful role in metastatic breast cancer care.

Surgery: The Traditional First Choice — and Its Limits

Surgical resection (removing the tumor) has been the first-choice local treatment for patients with a limited number of liver metastases from various primary cancers. For those who undergo complete surgical removal, the results can be impressive: reported 5-year survival rates range from 30% to 58%.

However, surgery has a significant limitation: only 10–30% of patients with liver metastases are eligible for resection. The reasons are both medical and technical — the number or location of tumors may make surgery unsafe, or the patient may not be healthy enough to withstand an operation. This leaves the majority of patients in need of alternative local treatment options.

Other Local Treatment Options and Their Drawbacks

To serve patients who are not surgical candidates, several other local ablative (tissue-destroying) techniques have been tried. These include:

• Radiofrequency ablation (RFA) — using heat to destroy tumors
• Transcatheter arterial chemoembolization (TACE) — delivering chemotherapy directly to the liver tumor through a catheter
• Cryotherapy — freezing tumors
• Radioembolization (Y90) — delivering radioactive beads to tumors via the bloodstream
• Thermal ablation
• Radiotherapy (RT)

Among these, RFA has been the most widely used ablation technique. But RFA has real limitations. It works best for lesions that are ≤3 cm in size — larger tumors are harder to completely destroy. Lesions located near major blood vessels or under the liver capsule (the outer lining) are also problematic. Perhaps most concerning, local recurrence after RFA is relatively high — up to 40% of patients — especially when tumors are located close to the liver hilum (the area where blood vessels and bile ducts enter the liver).

What Exactly Is SBRT?

Historically, radiation therapy played only a limited role in liver tumors. The liver is highly sensitive to radiation, and it was thought to be nearly impossible to deliver the high doses needed to destroy metastatic tumors without severely damaging healthy liver tissue.

Technological advances changed this. Stereotactic body radiation therapy (SBRT) is a technique that delivers a very conformal (precisely shaped) radiation dose to the tumor while giving only minimal radiation to the surrounding healthy liver. This allows normal liver tissue to be spared.

SBRT delivers high-dose radiation to the tumor in a small number of sessions — typically 1 to 6 fractions — in contrast to conventional radiation therapy, which uses low doses per treatment (usually 1.5–3 Gy) delivered to a larger volume over many weeks. SBRT is non-invasive, which makes it an attractive option for patients with liver oligometastases who are not eligible for surgery, RFA, or liver transplantation.

The growing body of research on liver SBRT — both prospective and retrospective — has shown encouraging results in terms of local control (keeping the treated tumor from growing back), toxicity (side effects), and overall survival.

Who Can Receive SBRT for Liver Metastases?

One of the advantages of SBRT over surgery is that it is less constrained by the location of tumors within the liver. Most clinical trials have defined SBRT as an alternative therapy or a salvage (rescue) therapy for inoperable or post-operative isolated liver metastases.

The most frequently used eligibility criteria in studies include:

• Fewer than or equal to 5 liver metastases
• Maximum tumor size of 6 cm
• Controlled or absent extra-hepatic disease (cancer outside the liver is under control or does not exist)
• Good performance status — meaning the patient is generally well-functioning (Eastern Cooperative Oncology Group [ECOG] score 0–1, or Karnofsky score >70)
• Adequate hepatic volume and liver function

Liver function has been defined in various ways across studies. Scorsetti and colleagues published a treatment algorithm that used two key indicators:

• The Child-Pugh score (A, B, or C — a standard measure of liver disease severity)
• "Free liver volume" — the amount of healthy liver that can be spared from radiation (>1,000 mL or <1,000 mL, and ≥700 mL or <700 mL)

Children-Pugh class A and a free liver volume greater than 1,000 mL were recommended as good indications for liver SBRT. To prevent side effects, the authors also required that tumors be located more than 8 mm away from other organs at risk (like the stomach or bowel). Interestingly, age was not included in selection criteria in almost all studies. In fact, this is precisely why SBRT is often chosen for elderly patients — many of whom are not suitable candidates for surgery.

How SBRT Is Delivered: The Treatment Procedure

Liver SBRT is technically challenging, primarily because of respiration-related organ motion — the liver moves as the patient breathes. Delivering precise radiation requires highly accurate dose planning, typically using multiple radiation beams arranged in coplanar (same plane) or non-coplanar (multiple planes) geometries.

Modern technology has made this easier. Intensity-modulated radiation therapy (IMRT), and more recently volumetric arc radiation therapy (VMAT) and the frameless robotic radiosurgery system (CyberKnife®), achieve dose distributions that closely fit the shape of the target while reducing exposure to other organs.

To account for respiratory movement, several processes are added to treatment planning:

1. Planning CT scans should be obtained at least above and below the region of interest, during both expiration and inspiration, in addition to free breathing. More recently, it has become recommended that four-dimensional CT (4D-CT) simulations be performed — this imaging technique tracks tumor movement throughout the breathing cycle to more accurately define the target.
2. MRI fusion — Since the liver is a solid organ, it is required to fuse magnetic resonance imaging (MRI) and/or 18-fluorodeoxyglucose positron emission tomography (FDG-PET)-CT with contrast-enhanced CT for precise targeting.
3. Image-guided radiation therapy (IGRT) — This is performed before each daily treatment session to reduce positioning errors. In selected patients, tiny fiducial markers (small gold seeds) are implanted in or near the tumor to help with target localization.

Beyond imaging, there are techniques that reduce respiratory movement itself:

• Oxygen inhalation
• Abdominal compression
• Respiratory arrest (breath-holding restriction)

In combination with these, two techniques reduce the influence of respiratory movement: respiratory synchronization (delivering radiation at a specific point in the breathing cycle) and moving-body tracking (the radiation beam follows the tumor as it moves). Because the CT imaging and target contouring methods differ depending on which respiratory management technique is used, each facility must develop its own optimal protocol. Practice guidelines for SBRT were published in 2010 by ASTRO (American Society for Radiation Oncology) and ACR (American College of Radiology).

Radiation Doses Used in SBRT

There is no single "standard" dose prescription for liver SBRT — and few large-scale reports or randomized phase III trials exist to definitively settle the question. The appropriate regimen depends on the size and location of the tumor and its relationship to nearby organs at risk. Across published studies, the dose for fractionated SBRT varies from 25 to 75 Gy in 3 to 6 fractions, with 3 fractions being the most common schedule.

For 3-fraction regimens, a key recommendation comes from Chang et al., who advised a total dose of at least 48 Gy to achieve sufficient local control (1-year local control greater than 90%). For single-fraction SBRT, several prospective trials have prescribed 14–30 Gy in one session.

Interestingly, most studies so far have not adjusted the prescribed dose based on the primary cancer type (breast, colon, lung, etc.). However, some researchers, including Yamashita et al., have proposed that dose escalation for metastatic liver tumors may be reasonable — noting that metastatic lung tumors require higher doses because they are relatively less radiosensitive. In the future, dosing might become more individualized as differences in radiation sensitivity between cancer types become clearer.

Protecting Healthy Organs: Dose Constraints

Because SBRT delivers very high doses of radiation, protecting the organs near the liver is critical. Scorsetti et al. published recommended dose constraints (safety limits) for organs at risk (OARs) during liver SBRT:

These constraints have been used in clinical trials with slight variations, and several published reports provide helpful guidance for clinical teams planning liver SBRT.

Combining SBRT with Systemic Therapy

Adding SBRT to systemic therapy could prolong survival, but the optimal sequence and timing of radiation and drug therapy for patients with oligometastatic breast cancer liver lesions is still being discussed. Reassuringly, no studies have reported increased adverse events when systemic therapy and SBRT are combined. This means patients on chemotherapy, hormone therapy, or targeted therapy can likely safely undergo SBRT — an important consideration for integrating this treatment into a comprehensive care plan.

Treatment Results: What Studies Show

An increasing number of retrospective and prospective studies have demonstrated the effectiveness of SBRT for liver metastases, including those originating from breast cancer. The reported results are impressive:

• 1-year local control rates range from 70% to 100%
• 2-year local control rates range from 60% to 90%
• Median overall survival after liver SBRT ranges widely, from 10 to 48 months

The variation between studies is thought to depend on differences in tumor volume, tumor histopathology (the specific cancer type), prior therapy, radiation dose, and fractionation regimen. Importantly, several reports looking at multiple primary cancer types have identified breast cancer origin as a favorable prognostic factor — meaning breast cancer liver metastases respond particularly well to SBRT compared to other cancers. Rusthoven and Mahadevan classified primary tumors into "favorable" and "unfavorable" groups based on survival outcomes, and breast cancer fell into the favorable group. Swaminath et al., analyzing 81 patients with 142 metastases, also reported that breast cancer subtype was one of the factors influencing time to local progression.

Here is a summary of key studies on SBRT for liver metastases, including those specifically focused on breast cancer:

Two studies focused exclusively on breast cancer liver metastases deserve special attention. Onal et al. combined liver SBRT with systemic treatment in 22 patients with 29 breast cancer liver metastases, reporting excellent results: 1- and 2-year overall survival rates of 85% and 57%, and 1- and 2-year local control rates of 100% and 88%, respectively. Scorsetti et al. treated lung or liver oligometastases from breast cancer with SBRT and achieved 1- and 2-year overall survival rates of 93% and 66%, with 1- and 2-year local control rates of 100% and 88%. The authors of these studies concluded that SBRT may be an effective and safe treatment option in selected patients with BCLM. Chang et al. further confirmed that higher prescription doses produce better local control, recommending a total dose greater than 48 Gy for 3-fraction regimens.

Predictors of Success: Who Benefits Most?

Not all patients respond equally to SBRT, and researchers have identified several prognostic factors associated with better outcomes. The most consistent favorable predictors of local control are:

• Tumor size — Smaller tumors respond better. A diameter of 30 or 40 mm is frequently used as the cut-off value in studies. Yamashita et al. found that maximum tumor diameter >30 mm versus ≤30 mm was the only significant factor for local control. Mahadevan et al. reported that smaller tumor volumes (<40 cm³) are associated with improved local control and overall survival.
• Prescription dose — Higher doses produce better outcomes. Chang et al. found that total dose (P=0.0015), dose per fraction (P=0.003), and biologically effective dose (BED) (P=0.004) all correlated with local control. Mahadevan and Yuan both reported that a BED ≥100 Gy was associated with improved local control (2-year local control rates of 77.2% vs. 59.6%). McCammon et al. demonstrated significant improvement with increasing dose: 3-year local control rates were 89.3% for lesions receiving 54–60 Gy, 59% for 36–53.9 Gy, and only 8.1% for less than 36 Gy (P<0.01).
• Histology (cancer type) — As noted, breast cancer is a favorable histology for SBRT of liver metastases.

Additional factors associated with favorable overall survival include good performance status, solitary metastasis (only one metastatic spot), metachronous metastases (cancer spread that occurred later, rather than at initial diagnosis), and receiving chemotherapy before SBRT.

Side Effects and Toxicity: How Safe Is SBRT?

Severe toxicity from liver radiation is rare — especially with SBRT. According to Ihnát et al., grade 3 side effects occur in less than 5% of SBRT cases.

Acute (short-term) side effects: The most common are grade 1–2 gastrointestinal symptoms — nausea, vomiting, abdominal pain, and peptic ulcers — experienced by 10–30% of patients. Depending on the treatment location, other less frequent side effects can include chest wall pain, dermatitis (skin irritation), pneumonia, and renal (kidney) dysfunction.

Late side effects: Late adverse events include gastrointestinal ulcers and perforations, bile duct stenosis (narrowing of bile ducts), pulmonary fibrosis (lung scarring), and renal fibrosis (kidney scarring). Fortunately, serious cases of any of these are rarely reported.

Radiation-Induced Liver Disease: A Key Concern

Radiation-induced liver disease (RILD) is an acute reaction that occurs between 2 weeks and 4 months after radiation therapy. It is characterized by anicteric ascites (fluid buildup in the abdomen without yellowing of the skin/eyes), along with elevation of alkaline phosphatase and liver transaminases (enzymes that signal liver damage). In severe cases, RILD can result in liver failure and death.

Older studies by Emami et al. reported the radiation doses that carry a 5% risk of RILD as 50 Gy, 35 Gy, and 30 Gy for one-third, two-thirds, and the whole liver, respectively. These criteria are still widely used. However, Lawrence et al. later argued that with proper restriction of the irradiated area of normal liver, it was possible to deliver more than 90 Gy without causing RILD. Dawson's research on 204 patients showed the 5% risk dose for RILD was 54 Gy when two-thirds of the liver was irradiated, and 100 Gy when only one-third was irradiated — substantially higher than earlier estimates.

The key takeaway: although RILD is the most limiting side effect of liver irradiation, its occurrence depends heavily on how much healthy liver tissue is exposed. It can be prevented by carefully limiting the radiation dose to normal liver tissue. After Méndez Romero et al. reported two cases of RILD after SBRT, very few additional cases have been described in liver SBRT studies. The recent very low incidence of RILD is likely a direct result of the extreme accuracy of radiation delivery achieved with SBRT.

Conclusions: Where SBRT Stands Today

Published data on SBRT for liver oligometastases demonstrate promising results, particularly in terms of local control and safety — even though most patients treated in these studies had been deemed inoperable before treatment. The authors of this review conclude that SBRT can be considered a safe and feasible alternative to surgical resection and ablation in selected patients with breast cancer liver metastases.

For patients, this means that a diagnosis of breast cancer liver metastases no longer automatically rules out effective local treatment. SBRT offers a non-invasive option with excellent tumor control, a low risk of serious side effects, and meaningful survival outcomes.

Limitations of the Current Evidence

The authors are candid about the limitations of the existing research. The number of patients in studies focusing specifically on breast cancer liver metastases is small, and observation periods are relatively short. The patient selection criteria and the optimal dose and fractionation for liver SBRT are still under investigation. There is currently no randomized phase III trial data for SBRT in liver metastases. The authors state clearly that prospective randomized trials and further studies are required to define the appropriate targets and methods for SBRT and to establish its definitive role in BCLM.

Recommendations for Patients

Based on this review, here are some practical points for patients with breast cancer liver metastases — and for anyone exploring treatment options:

1. Ask about SBRT if surgery isn't an option. If you have a limited number of liver metastases (5 or fewer, each ≤6 cm) and are not a candidate for surgery or ablation, SBRT is a well-supported alternative that offers high local control rates with minimal side effects.
2. Know that breast cancer responds well to SBRT. Multiple studies classify breast cancer as a favorable tumor type for this treatment. Don't assume your cancer is inherently "hard to treat" in the liver.
3. Expect a brief, non-invasive treatment course. Most SBRT regimens involve 3 sessions, though some range from 1 to 8 sessions depending on the facility and tumor specifics. There's no cutting and typically no hospital stay.
4. Ask about your liver function and tumor location. Good candidates typically have Child-Pugh A liver function, enough healthy liver volume (>700–1,000 mL that can be spared from radiation), and tumors located at least 8 mm away from sensitive organs.
5. Continue your systemic therapy. SBRT is intended to complement — not replace — chemotherapy, hormone therapy, or targeted therapy. Research so far shows no increased side effects when combining SBRT with systemic treatment.
6. Expect mild, manageable side effects. Nausea, vomiting, or abdominal discomfort occur in 10–30% of patients but are typically mild (grade 1–2). Serious side effects happen in fewer than 5% of cases.
7. Discuss dosing with your radiation oncologist. For 3-fraction plans, a total dose of at least 48 Gy (or a biologically effective dose of ≥100 Gy) is associated with the best local control.

Frequently Asked Questions

What is SBRT and how does it treat breast cancer that has spread to the liver?

Stereotactic body radiotherapy (SBRT) delivers precise, high-dose radiation to tumors in a few sessions, usually 1 to 6, while sparing surrounding healthy liver. It is non-invasive and offers an alternative to surgery or ablation. For breast cancer liver metastases, studies report excellent local control with minimal serious side effects.

Am I eligible for SBRT for liver metastases from breast cancer?

Typical eligibility in studies includes up to 5 liver metastases, each no larger than 6 cm, controlled or absent cancer outside the liver, good performance status, and adequate liver function, often Child-Pugh class A with more than 700–1000 mL of healthy liver that can be spared. Tumors should sit at least 8 mm from sensitive organs.

How is SBRT delivered? How many treatments are needed?

Before each session, imaging like CT and MRI is used to target the tumor precisely. Techniques reduce motion from breathing, such as abdominal compression or tracking the tumor. Most SBRT regimens involve 3 sessions, though some range from 1 to 8, depending on the facility and tumor specifics.

What side effects can I expect from SBRT for liver metastases?

Mild gastrointestinal symptoms like nausea, vomiting, or abdominal discomfort occur in 10–30% of patients, typically grade 1–2. Serious side effects happen in fewer than 5% of cases. A rare but important risk is radiation-induced liver disease, which can be prevented by limiting healthy liver exposure.

How well does SBRT work for breast cancer that has spread to the liver?

Reported 1-year local control rates range from 70% to 100%, and 2-year rates from 60% to 90%. Studies focusing on breast cancer liver metastases, such as a trial of 22 patients, showed 1- and 2-year local control of 100% and 88%. Breast cancer is considered a favorable type for SBRT.

Can I continue chemotherapy or hormone therapy during SBRT?

Yes. SBRT is intended to complement, not replace, systemic therapy. No studies have reported increased side effects when combining SBRT with chemotherapy, hormone therapy, or targeted therapy. The optimal timing and sequence are still being discussed, so ask your oncologist about your specific treatment plan.

What radiation dose should I receive for breast cancer liver metastases?

No single standard dose exists. For 3-fraction SBRT, a total dose of at least 48 Gy is recommended to achieve more than 90% 1-year local control. Biologically effective dose of at least 100 Gy has also been linked to better local control. Your radiation oncologist will tailor dosing to tumor size, location, and nearby organs.

Should I get a second opinion to find out if I really need surgery for breast cancer liver metastases, or is SBRT an alternative option for me?

For breast cancer that has spread only to the liver, surgery has been the traditional first choice, but only 10–30% of patients are eligible. In selected patients with up to five liver metastases no larger than 6 cm, SBRT offers a non-invasive alternative, with one-year local control rates of 70–100% and serious side effects in fewer than 5% of patients. A second opinion can help clarify whether surgery is truly necessary or whether SBRT is suitable for your specific liver function and tumor location. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

This patient-friendly article is based on the following peer-reviewed research:

• Original Article Title: Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer